W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH PROPATEN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY
|
Back to Search Results |
|
Catalog Number PAJR060702E |
Device Problems
Obstruction of Flow (2423); Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problem
Obstruction/Occlusion (2422)
|
Event Date 07/03/2023 |
Event Type
Injury
|
Manufacturer Narrative
|
Patient information (id, status) including preexisting medical condition(s) and medications was requested but remains unavailable.C1: cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.H3: code "other" was selected as the medical device remains implanted.Return not possible.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
Event Description
|
On (b)(6) 2023, a gore® viabahn® endoprosthesis with propaten bioactive surface was implanted for dialysis access in a study patient's arm.The anatomical location wasn't specified.No adverse event was recorded during the whole procedure, the target vessel access was successfully obtained and a pre-dilation performed and at least a normal hemodialysis session was achieved following the procedure.According to reports, an (b)(6) 2023, an adverse event termed "the graft appears occluded from the arterial anastomosis and remains occluded throughout" was discovered.A reintervention was performed and the primary relationship was reported as disease related.
|
|
Manufacturer Narrative
|
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.Emdr section h6 codes updated to reflect results of investigation.Section h6: code d12-according to the gore® viabahn® endoprosthesis with propaten bioactive surface instructions for use (ifu), possible adverse events and complications that may occur with the use of this device, or in any endovascular procedure and require intervention include, but are not limited to: occlusion (thrombosis and/or stenosis) of endoprosthesis or vessel.
|
|
Search Alerts/Recalls
|
|
|